These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 17722967)

  • 21. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
    Toprani A; Fonseca V
    Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinedione safety.
    Kung J; Henry RR
    Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: Thiazolidinediones and heart failure.
    Chaggar PS; Shaw SM; Williams SG
    Diab Vasc Dis Res; 2009 Jul; 6(3):146-52. PubMed ID: 20368206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mode of action of thiazolidinediones.
    Hauner H
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S10-5. PubMed ID: 11921433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent findings concerning thiazolidinediones in the treatment of diabetes.
    Boden G; Zhang M
    Expert Opin Investig Drugs; 2006 Mar; 15(3):243-50. PubMed ID: 16503761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
    Kudzma DJ
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT; Sharma AM
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
    Mudaliar S; Chang AR; Henry RR
    Endocr Pract; 2003; 9(5):406-16. PubMed ID: 14583425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
    Guan Y; Hao C; Cha DR; Rao R; Lu W; Kohan DE; Magnuson MA; Redha R; Zhang Y; Breyer MD
    Nat Med; 2005 Aug; 11(8):861-6. PubMed ID: 16007095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances on PPARĪ³ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 35. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
    Lecka-Czernik B
    Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.
    Soccio RE; Chen ER; Lazar MA
    Cell Metab; 2014 Oct; 20(4):573-91. PubMed ID: 25242225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones.
    Liu Y; Yan X; Mao G; Fang L; Zhao B; Liu Y; Tang H; Wang N
    J Proteome Res; 2013 Dec; 12(12):5634-41. PubMed ID: 24164426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.